分化型甲状腺癌外照射放疗联合或不联合同步化疗的长期结果
该回顾性队列研究纳入1989至2023年327例复发、大体残留或未切除的分化型甲状腺癌患者,比较单纯放疗与同步放化疗的长期结局。两组4年局部区域控制、无远处转移生存和总生存均无差异,同步放化疗组3级以上急性皮炎更多,且有6例在酪氨酸激酶抑制剂治疗后发生气管食管瘘。
要点
- 同步放化疗组与单纯放疗组4年局部区域控制、无远处转移生存和总生存均无显著差异。
- 同步放化疗组3级以上急性皮炎发生率为29%,高于单纯放疗组的10%(P<0.0001)。
- 8例发生气管食管瘘,其中6例接受了同步放化疗后酪氨酸激酶抑制剂治疗。
核心结论
- 在这项回顾性研究中,同步放化疗较单纯放疗未显示出任何获益,尽管接受同步放化疗的患者疾病更严重。
- 除同步放化疗患者接受酪氨酸激酶抑制剂治疗后气管食管瘘发生更多外,两组晚期毒性相似。
- 需要进一步研究以明确哪些患者可能从同步放化疗中获益。
研究设计与样本
- 回顾性队列研究,纳入1989年至2023年327例复发、大体残留或未切除的分化型甲状腺癌患者,接受单纯放疗或同步放化疗。
- 不完全切除和/或不良好组织学的患者优先接受同步放化疗。
- 采用Kaplan-Meier法评估局部区域控制、无远处转移生存和总生存。
主要发现
- 同步放化疗组(n=153)女性占46%,年龄61.6±11.7岁;单纯放疗组(n=174)女性占48%,年龄66.8±12.6岁。
- 总体中位随访109.7个月(置信区间100.3-123.5个月)。
- 4年局部区域控制率:单纯放疗组89.0% vs 同步放化疗组86.6%(P=0.76);4年无远处转移生存率:单纯放疗组64.2% vs 同步放化疗组54.5%(P=0.08);4年总生存率:单纯放疗组58.5% vs 同步放化疗组56.9%(P=0.28)。
- 3级以上急性皮炎:同步放化疗组29% vs 单纯放疗组10%(P<0.0001)。
- 8例发生气管食管瘘,其中6例接受同步放化疗后酪氨酸激酶抑制剂治疗;气管食管瘘在酪氨酸激酶抑制剂开始后中位7.3个月(范围0.5-17.0个月)发生。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: A rare group of patients with differentiated thyroid cancers (DTCs) will have gross residual disease or recurrence following the standard primary therapies of surgical resection and radioactive iodine. In these patients with advanced DTC no longer amenable to further surgery, systemic, or radioactive iodine therapies, external beam radiation therapy (RT) is considered. Whether to add concurrent chemotherapy (CRT) to radiation for patients with advanced DTC remains unclear. We review the long-term follow-up of the largest single-institution experience on the use of RT alone versus CRT in advanced DTC. Methods: From 1989 to 2023, 327 patients with recurrent, gross residual, or unresected DTC were treated with RT alone or CRT. Patients with incomplete resection and/or unfavorable histology were preferentially treated with CRT. For this retrospective cohort study, locoregional control (LRC), distant metastasis-free survival (DMFS), and overall survival (OS) were evaluated using the Kaplan-Meier method. Results: CRT patients (n = 153) were 46% female and 61.6 ± 11.7 years old versus RT alone (n = 174) were 48% female and 66.8 ± 12.6 years old. Overall median follow-up was 109.7 months [confidence interval 100.3-123.5 months]. There were no differences in 4- and 10-year LRC, DMFS, or OS rates between groups (4-year LRC 89.0% RT alone vs. 86.6% CRT, p = 0.76; 4-year DMFS: 64.2% RT alone vs. 54.5% CRT, p = 0.08; 4-year OS: 58.5% RT alone vs. 56.9% CRT, p = 0.28). Worse grade 3+ acute dermatitis was reported with CRT (29% CRT vs. 10% RT alone, p < 0.0001). Eight patients developed a tracheoesophageal fistula (TEF), six of whom received CRT followed by tyrosine kinase inhibitor (TKI) therapy. TEF developed at a median of 7.3 months (range = 0.5-17.0 months) after TKI initiation. There were no differences in other acute toxicities, any late toxicities, rates of tracheostomy tube, percutaneous endoscopic gastrostomy (PEG) tube within 60 days of RT, or PEG tube persistence past one year. Conclusion: CRT did not demonstrate any benefit over RT alone in this retrospective study, although patients treated with CRT had worse disease. Late toxicities were similar, aside from greater TEF development after TKI therapy in CRT patients. Further research is necessary to elucidate who may benefit from CRT.
引用
- Choi J, Sherman E, Dee EC, et al. Long-Term Results of External Beam Radiation Therapy with or Without Concurrent Chemotherapy in Differentiated Thyroid Cancer. Thyroid. 2025. PMID: 40504742. doi:10.1089/thy.2025.0052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。